BARCELONA, July 12, 2012 /CNW/ - This site is part of the http://www.esteve.com corporate web portal
ESTEVE's new website provides consise and updated information on its
projects under development. Among these is the S1RA (Sigma-1 Receptor
Antagonist), a new chemical entity, presently in Clinical Phase II, for
treating several types of pain
In addition to defining the Company's main lines of research, this new
website also discloses the Company's different and innovative models of
ESTEVE announces the launch of a new website (http://www.esteve.es/EsteveFront/IDI.do?lng=en) with the purpose of communicating the Company's R&D and the innovative
models of collaboration currently implemented. Newly formatted and
fully integrated in the http://www.esteve.com web portal, this site reinforces the commitment of ESTEVE to R&D with
emphasis on a solid strategy to provide new therapeutic solutions for
unmet medical needs in highly prevalent diseases of high social impact.
With its primary focus in analgesia, ESTEVE is developing innovative
therapies for pain. Two projects are presently undergoing clinical
development for the treatment of neuropathic pain and moderate to
severe acute and chronic pain.
One of these projects involves S1RA, a highly selective Sigma-1 Receptor Antagonist that offers a new approach and a new mechanism of action in a field
(neuropathic pain) strongly in need of novel, more effective and safer
The new website also describes the innovative partnering strategy in R&D
as well as ESTEVE's network of excellence built through unique collaborative models. This network includes
different types of alliances, from public-private partnerships -such as
the HIVACAT program to develop an effective vaccine against HIV and the
Sanfilippo project to develop a treatment for a rare childhood disease-
to R&D consortiums such as Neogenius for pain research.
One of the key features of this site is its attractively designed
interface for portfolio presentation, which includes the various
ongoing R&D programs, i.e. in-house projects in analgesia, projects in
collaboration with other centers or companies, and in-licensed
With language and information customized for each audience, this new
website provides specific information for scientists, healthcare
providers, industry partners, patients and other stakeholders.
ESTEVE is a leading chemical-pharmaceutical group in Spain and has a
strong international presence. Ever since its foundation in 1929,
ESTEVE has been firmly committed to excellence and has been using its
best efforts to promote health and improve people's quality of life.
For further information:
M Angels Valls Tel. +34-93-446-62-60, e.mail firstname.lastname@example.org